deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02982694

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

A Phase II Open-label Study With the Anti-PD-L1 Atezolizumab Monoclonal Antibody in Combination With Bevacizumab in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and MSI-like Molecular Signature

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Chemotherapy ColoRectal Cancer MSI Resistance, APC
Interventions Atezolizumab Bevacizumab
Updated 13 times since 2017 Last updated: Sep 25, 2025 Started: Nov 24, 2017 Primary completion: Nov 27, 2020 Completion: Nov 27, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) is inferior to the expected, and this situation is very unlikely to be reversed if the trial is fully completed.

Other terminated trials from European Organisation for Research and Treatment of Cancer - EORTC

See all terminations from European Organisation for Research and Treatment of Cancer - EORTC

A PHASE2 clinical study on Chemotherapy and ColoRectal Cancer, this trial is terminated or withdrawn. The trial is conducted by European Organisation for Research and Treatment of Cancer - EORTC and has accumulated 13 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Nov 2020 · 17 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

13 versions recorded

  1. Nov 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Nov 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 8 earlier versions

  1. Nov 2021 — Dec 2021 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  2. Jan 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  3. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Jun 2019 — Nov 2020 [monthly]

    Recruiting PHASE2

  5. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  6. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jun 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE2

  8. Jan 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Organisation for Research and Treatment of Cancer - EORTC
  • Vall d'Hebron Institute of Oncology
Data source: Vall d'Hebron Institute of Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations